Anika Therapeutics (NASDAQ: ANIK) updates $50M revolving credit line terms
Rhea-AI Filing Summary
Anika Therapeutics, Inc. entered into a Fifth Amendment to its Credit Agreement with Bank of America, N.A. on July 10, 2026. The Amended Agreement provides a $50.0 million senior revolving line of credit with a maturity date of July 10, 2031.
Subject to specified conditions and lender approval, Anika may request up to an additional $50.0 million in commitments for a maximum aggregate commitment of $100.0 million. Borrowings bear interest at SOFR plus 0.25%–1.25%, based on Anika’s consolidated leverage ratio. A 0.20%–0.30% annual commitment fee applies to the unused facility, payable quarterly in arrears. Loan origination costs are amortized over the five-year term. The facility includes customary covenants and events of default, with financial covenants tied to leverage and interest coverage, and is secured by a first priority lien on substantially all assets other than certain intangible assets.
Positive
- None.
Negative
- None.
Filing Explained
The July 14 filing reports that Anika entered into the Fifth Amendment on July 10, establishing a
8-K Event Classification
3 items: 1.01, 2.03, 9.01
3 items
Item 1.01
Entry into a Material Definitive Agreement
Business
The company signed a significant contract such as a merger agreement, credit facility, or major partnership.
Item 2.03
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement
Financial
The company incurred a new significant debt or off-balance-sheet obligation.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
Senior revolving credit line: $50.0 million
Additional commitments available: $50.0 million
Maximum aggregate commitment: $100.0 million
+4 more
7 metrics
Senior revolving credit line
$50.0 million
Commitment under Amended Agreement with Bank of America, N.A.
Additional commitments available
$50.0 million
Potential incremental commitments subject to conditions and lender approval
Maximum aggregate commitment
$100.0 million
Total possible facility size if additional commitments are approved
Interest margin over SOFR
0.25%–1.25%
Spread determined by consolidated leverage ratio at borrowing
Commitment fee on unused amount
0.20%–0.30% per annum
Applied to actual daily unused facility balance, payable quarterly
Maturity date
July 10, 2031
Stated maturity of the senior revolving line of credit
Term for amortizing origination costs
five-year term
Loan origination costs amortized over the term of the Amended Agreement
Key Terms
Fifth Amendment to Credit Agreement, senior revolving line of credit, Secured Overnight Financing Rate, commitment fee, +2 more
6 terms
Fifth Amendment to Credit Agreement financial
"entered into a Fifth Amendment to Credit Agreement, or the Fifth Amendment"
senior revolving line of credit financial
"serves as administrative agent...for a $50.0 million senior revolving line of credit"
Secured Overnight Financing Rate financial
"bear interest at a rate equal to (a) the Secured Overnight Financing Rate"
A secured overnight financing rate (SOFR) is a daily benchmark interest rate that reflects the cost of borrowing cash overnight using U.S. Treasury securities as collateral. Think of it as the market price to “rent” cash for a day with a very safe pledge, similar to paying a short-term rental fee for money backed by government bonds. Investors track SOFR because it underpins pricing for loans, bonds and derivatives, so movements change borrowing costs, interest income and the valuation of interest-rate–linked positions.
commitment fee financial
"We have agreed to pay a commitment fee in an amount equal to 0.20% to 0.30%"
A commitment fee is a charge a lender applies to a borrower for keeping a loan or line of credit available, even before any money is drawn. Think of it as a reservation fee for borrowing power; the borrower pays to ensure funds will be there when needed. Investors care because it adds to a company’s borrowing cost, affects cash flow and liquidity, and can signal lenders’ willingness to extend credit.
first priority lien financial
"The Lenders have been granted a first priority lien and security interest"
A first priority lien is a legal claim that gives one lender or creditor the top spot to be paid from specific assets if a borrower defaults or goes bankrupt. Think of it like holding the first place ticket in a line for a limited payout — that creditor gets paid before any others from the proceeds of the pledged assets. For investors, knowing who holds a first priority lien helps gauge how much money could realistically be recovered and how risky a company's debt or secured investment is.
interest coverage ratio financial
"restrictions governing our leverage ratio and interest coverage ratio"
A measure of how easily a company can pay the interest on its debt, calculated by comparing the earnings it generates from operations to the interest it owes. It matters to investors because a higher ratio means the company can comfortably meet interest payments — like having several paychecks set aside to cover your rent — while a low ratio signals greater risk of missed payments or financial strain.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What new credit facility terms did Anika Therapeutics (ANIK) agree to on July 10, 2026?
Anika Therapeutics entered a Fifth Amendment to its Credit Agreement, providing a $50.0 million senior revolving credit line maturing on July 10, 2031. The agreement updates lending terms with Bank of America, N.A., including interest margins and covenant structure.
How large is Anika Therapeutics' potential borrowing capacity under the amended credit agreement (ANIK)?
The Amended Agreement provides an initial $50.0 million senior revolver, with the option to request up to an additional $50.0 million. If fully approved by the lenders, this would allow a maximum aggregate commitment of $100.0 million under the facility.
What interest rate will apply to borrowings under Anika Therapeutics' amended facility (ANIK)?
Borrowings will bear interest at SOFR plus 0.25% to 1.25%, depending on Anika’s consolidated leverage ratio. This floating rate structure links the spread directly to Anika’s leverage at the time each borrowing is made under the Amended Agreement.
What fees does Anika Therapeutics (ANIK) pay on unused amounts of its credit line?
Anika will pay a 0.20% to 0.30% annual commitment fee on the actual daily unused amount of the facility. The applicable rate depends on the company’s consolidated leverage ratio and is payable quarterly in arrears to the lenders.
What collateral and covenants support Anika Therapeutics' amended credit agreement (ANIK)?
Lenders receive a first priority lien and security interest in substantially all of Anika’s assets, excluding certain intangibles. The agreement includes customary affirmative and negative covenants, with financial tests on leverage and interest coverage, plus restrictions on additional debt, liens, and certain transactions.